Literature DB >> 25392225

Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Stefan J Halbherr1, Thomas H Ludersdorfer1, Meret Ricklin1, Samira Locher1, Marianne Berger Rentsch1, Artur Summerfield1, Gert Zimmer2.   

Abstract

UNLABELLED: The envelope of influenza A viruses contains two large antigens, hemagglutinin (HA) and neuraminidase (NA). Conventional influenza virus vaccines induce neutralizing antibodies that are predominantly directed to the HA globular head, a domain that is subject to extensive antigenic drift. Antibodies directed to NA are induced at much lower levels, probably as a consequence of the immunodominance of the HA antigen. Although antibodies to NA may affect virus release by inhibiting the sialidase function of the glycoprotein, the antigen has been largely neglected in past vaccine design. In this study, we characterized the protective properties of monospecific immune sera that were generated by vaccination with recombinant RNA replicon particles encoding NA. These immune sera inhibited hemagglutination in an NA subtype-specific and HA subtype-independent manner and interfered with infection of MDCK cells. In addition, they inhibited the sialidase activities of various influenza viruses of the same and even different NA subtypes. With this, the anti-NA immune sera inhibited the spread of H5N1 highly pathogenic avian influenza virus and HA/NA-pseudotyped viruses in MDCK cells in a concentration-dependent manner. When chickens were immunized with NA recombinant replicon particles and subsequently infected with low-pathogenic avian influenza virus, inflammatory serum markers were significantly reduced and virus shedding was limited or eliminated. These findings suggest that NA antibodies can inhibit virus dissemination by interfering with both virus attachment and egress. Our results underline the potential of high-quality NA antibodies for controlling influenza virus replication and place emphasis on NA as a vaccine antigen. IMPORTANCE: The neuraminidase of influenza A viruses is a sialidase that acts as a receptor-destroying enzyme facilitating the release of progeny virus from infected cells. Here, we demonstrate that monospecific anti-NA immune sera inhibited not only sialidase activity, but also influenza virus hemagglutination and infection of MDCK cells, suggesting that NA antibodies can interfere with virus attachment. Inhibition of both processes, virus release and virus binding, may explain why NA antibodies efficiently blocked virus dissemination in vitro and in vivo. Anti-NA immune sera showed broader reactivity than anti-HA sera in hemagglutination inhibition tests and demonstrated cross-subtype activity in sialidase inhibition tests. These remarkable features of NA antibodies highlight the importance of the NA antigen for the development of next-generation influenza virus vaccines.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25392225      PMCID: PMC4300740          DOI: 10.1128/JVI.02949-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

Review 2.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

3.  Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors.

Authors:  Xueyong Zhu; Ryan McBride; Corwin M Nycholat; Wenli Yu; James C Paulson; Ian A Wilson
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

4.  Characterization of the neuraminidase of the H1N1/09 pandemic influenza virus.

Authors:  T Gerlach; L Kühling; J Uhlendorff; V Laukemper; T Matrosovich; V Czudai-Matwich; F Schwalm; H-D Klenk; M Matrosovich
Journal:  Vaccine       Date:  2012-10-09       Impact factor: 3.641

5.  Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.

Authors:  Steven Rockman; Lorena E Brown; Ian G Barr; Brad Gilbertson; Sue Lowther; Anatoly Kachurin; Olga Kachurina; Jessica Klippel; Jesse Bodle; Martin Pearse; Deborah Middleton
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

Review 6.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

7.  A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Jia-Tsrong Chan; Yu-Chih Yang; Ji-Rong Yang; Ming-Tsan Liu; Ho-Sheng Wu; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

8.  Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate.

Authors:  Mary P Hall; James Unch; Brock F Binkowski; Michael P Valley; Braeden L Butler; Monika G Wood; Paul Otto; Kristopher Zimmerman; Gediminas Vidugiris; Thomas Machleidt; Matthew B Robers; Hélène A Benink; Christopher T Eggers; Michael R Slater; Poncho L Meisenheimer; Dieter H Klaubert; Frank Fan; Lance P Encell; Keith V Wood
Journal:  ACS Chem Biol       Date:  2012-08-30       Impact factor: 5.100

Review 9.  Influenza neuraminidase.

Authors:  Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2011-11-16       Impact factor: 4.380

10.  Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus.

Authors:  Stefan J Halbherr; Terza Brostoff; Merve Tippenhauer; Samira Locher; Marianne Berger Rentsch; Gert Zimmer
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

View more
  23 in total

1.  The role of cell surface expression of influenza virus neuraminidase in induction of human lymphocyte apoptosis.

Authors:  Joan E Nichols; Jean A Niles; Elisa H Fleming; Norbert J Roberts
Journal:  Virology       Date:  2019-06-10       Impact factor: 3.616

2.  Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge.

Authors:  Sinthujan Jegaskanda; Catherine Luke; Heather D Hickman; Mark Y Sangster; Wendy F Wieland-Alter; Jacqueline M McBride; Jon W Yewdell; Peter F Wright; John Treanor; Carrie M Rosenberger; Kanta Subbarao
Journal:  J Infect Dis       Date:  2016-06-28       Impact factor: 5.226

Review 3.  Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms.

Authors:  Jing Jin; Graham Simmons
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

4.  Synthetically derived bat influenza A-like viruses reveal a cell type- but not species-specific tropism.

Authors:  Étori Aguiar Moreira; Samira Locher; Larissa Kolesnikova; Hardin Bolte; Teresa Aydillo; Adolfo García-Sastre; Martin Schwemmle; Gert Zimmer
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

5.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

6.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

7.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

8.  Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Authors:  E R Job; M Schotsaert; L I Ibañez; A Smet; T Ysenbaert; K Roose; M Dai; C A M de Haan; H Kleanthous; T U Vogel; X Saelens
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

9.  Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Haoming Xu; Gene S Tan; Ariana Hirsh; Karl A Brokstad; Rebecca J Cox; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2015-03-10       Impact factor: 7.867

10.  Characterisation of the epidemic strain of H3N8 equine influenza virus responsible for outbreaks in South America in 2012.

Authors:  Edsel Alves Beuttemmüller; Alana Woodward; Adam Rash; Luis Eduardo Dos Santos Ferraz; Alice Fernandes Alfieri; Amauri Alcindo Alfieri; Debra Elton
Journal:  Virol J       Date:  2016-03-19       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.